Provided by Tiger Trade Technology Pte. Ltd.

Arrowhead Pharmaceuticals

58.60
-2.1300-3.51%
Volume:529.54K
Turnover:31.31M
Market Cap:8.25B
PE:-25.66
High:60.73
Open:60.04
Low:58.22
Close:60.73
52wk High:95.49
52wk Low:34.61
Shares:140.86M
Float Shares:122.00M
Volume Ratio:0.83
T/O Rate:0.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2838
EPS(LYR):-0.0122
ROE:-55.21%
ROA:-8.10%
PB:17.73
PE(LYR):-4,806.04

Loading ...

Analysts Conflicted on These Healthcare Names: Roche Holding AG (OtherRHHVF), Humana (HUM) and Arrowhead Pharmaceuticals (ARWR)

TIPRANKS
·
Yesterday

Should FDA Fast Track Entry Require Action From Arrowhead Pharmaceuticals (ARWR) Investors?

Simply Wall St.
·
Oct 11

Arrowhead’s Plozasiran Trial Completion Signals a Pivotal Moment for ARWR Investors

TIPRANKS
·
Oct 10

Top 3 Biotech Stocks To Watch In October 2026

Simply Wall St.
·
Oct 09

Sector Update: Healthcare Stocks Flat to Higher Pre-Bell Wednesday

MT Newswires Live
·
Oct 07

Arrowhead announces US FDA granted plozasiran entry into STAR program

TIPRANKS
·
Oct 07

Arrowhead Says FDA Grants Plozasiran Entry into STAR Pilot Program for Severe Hypertriglyceridemia sNDA

Reuters
·
Oct 07

Arrowhead Pharmaceuticals - to Submit Snd a for Plozasiran in Shtg to FDA by Year-End 2026

THOMSON REUTERS
·
Oct 07

Arrowhead Pharmaceuticals Granted Entry in the FDA Star Pilot Program for Plozasiran in Severe Hypertriglyceridemia

THOMSON REUTERS
·
Oct 07

What Comes Next For Arrowhead Pharmaceuticals After The 78% Run

Simply Wall St.
·
Oct 04

Movement Alert|Arrowhead Pharmaceuticals Falls 6.35% in Pre-Market Trading, Trading at $66.86

Market Focus
·
Sep 30

Arrowhead Pharmaceuticals to Host R&D Webinar on ARO-MAPT Interim Phase 1/2a Data

Reuters
·
Sep 29

Arrowhead’s Plozasiran Trial Completion Marks a Key Catalyst in the Triglyceride Market

TIPRANKS
·
Sep 26

Arrowhead Pharmaceuticals Price Target Announced at $74.00/Share by Goldman Sachs

Dow Jones
·
Sep 24

Movement Alert|Arrowhead Pharmaceuticals Falls 6.92% in Regular Trading, Trading at $66.71

Market Focus
·
Sep 24

These 'Moonshot' Biotech Stocks Could Break Out, Morgan Stanley Says. What Must Go Right.

Dow Jones
·
Sep 23

Arrowhead Pharmaceuticals (ARWR) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Sep 22

Movement Alert|Arrowhead Pharmaceuticals Falls 5.41% in Regular Trading, Conservative Wording in Dual-Function RNAi Interim Data Extends Selling Pressure

Market Focus
·
Sep 17

Arrowhead Pharmaceuticals Inc Stock (ARWR) Moved Down by 8.93% on Sep 15: What Investors Need To Know

TradingKey
·
Sep 16

Movement Alert|Arrowhead Pharmaceuticals Falls 8.95% in Regular Trading, Interim Data for Dual-Function RNAi Therapy Triggers Sell-Off

Market Focus
·
Sep 16